WESTMINSTER, Colo., April 21, 2015 (GLOBE NEWSWIRE) -- GeneThera Inc. (OTC:GTHR) announced today that has appointed Bruce Winsett and Jorgen Frandsen as members of the Company's Board of Directors
Bruce Winsett is an Aerospace Engineer at Lockheed Martin with over 30 years of experience in robotic technology ranging from Military Space Programs to NASA planetary missions and Launch System support. Bruce has developed complex software systems such graphical user interface software (Lab VIEW) to remotely control spacecraft's robotic components. Bruce holds a Master of Science in Physics from Purdue University and he has been recognized as a Lockheed Martin Space System Co. ATLO Software Center of Excellence Scientist.
Jorgen Frandsen is a Biomedical Engineer with over 35 years of experience in global operations, new technology and product development including robotic technology. He was Director of R &D at StorageTeck, VP of Product Development at Exabyte and VP of New Product Introduction at Maxtor Inc. He is currently President of Rev Zero Engineering a biomedical contract engineering company. Jorgen holds an MsEE from the University of Colorado.
Tony Milici Chairman and CEO of GeneThera commented on the news. "The appointment of Bruce and Jorgen on GeneThera' Board of Directors sets our company apart in the field of biotechnology. GeneThera's goal is to became a leader in the emerging field of Molecular Robotics and I do believe that Bruce and Jorgen extensive expertise in the biomedical and robotic engineering will allows us to achieve that goal. The potential of Molecular Robotics in molecular diagnostics and therapeutics is enormous. We recently entered into an exclusive agreement with Hudson Robotics, a leader in integrated robotic technology. In collaboration with Hudson we are developing an Integrated Automated Robotic System (IARS) for molecular diagnostics of paratuberculosis and tuberculosis in animals and dairy products. Bruce and Jorgen addition to our team will further enhance GeneThera's technology capabilities in Molecular Robotics."
Mycobacterium Avium Paratuberculosis (MAP) is the causative agent of Johne's disease also known as Paratuberculosis. Johne's Disease (JD) is a globally devastating incurable chronic inflammatory intestinal disease of dairy cow, sheep and goats. It has been estimated that over 70% of the dairy cowherd in the US alone are infected with MAP. A large number of studies have shown a relation between JD and Crohn's disease, a severe and possibly lethal chronic inflammatory disease of the human intestine. MAP is resistant to standard pasteurization procedures. Recent studies have also shown baby formula samples were positive for MAP infection.
About GeneThera, Inc.
GeneThera, Inc. is a molecular biotechnology company located in Westminster, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES and Johne's disease management system, HERDCHECK, designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES and HERDCHECK systems are designed for a host of individual diseases, the current priority being Johne's disease.
This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.